CAPRICOR THERAPEUTICS, INC. - 8-K Filing
The Lancet published HOPE-3 Phase 3 trial results for Capricor's Deramiocel in DMD, showing a 54% slowing of upper limb decline and cardiac benefits; FDA issued one observation during BIMO inspection. (Items: 8.01 Other Events)
Tickers: $CAPR